RANI READ THE FULL RANI RESEARCH REPORT On November 6th, Rani Therapeutics Holdings, Inc. (NASDAQ:RANI) reported third ...

Full results from the Phase 2 REGEN-007 study of rilparencel were recently presented as a late-breaking clinical trial at the American Society of ...

The 2026 Nissan Sentra looks quite different than the 2025 version. Yet, underneath, it's relatively unchanged. Which leads ...

Acetylation of lysine residues in the tail domain of histone H3 is well characterized, but lysine residues in the histone globular domain are also acetylated. Histone modifications in globular domain ...

Gevo reported a $3.7 million loss from operations for the three months ended September 30, 2025, and positive Adjusted EBITDA 1 of approximately $6.7 million for the three months ended September 30, ...

The deadly legacy of Cold War uranium mines looms over better regulated operations near Navajo Nation land in Arizona.

In the Phase III results presented and published today, olezarsen demonstrated rapid, substantial and significant reductions in triglycerides by up to 72% on top of standard of care and reduced the ...

Q4 2025 Earnings Call November 10, 2025 9:00 AM ESTCompany ParticipantsJon KatholDonnie King - President, CEO & ...

WVE-007, an INHBE GalNAc-siRNA for obesity designed to drive fat loss while preserving muscle mass, achieved dose-dependent, mean reductions of Activin E of up to 85% in INLIGHT clinical trial, exceed ...